EA201891091A1 - Соединения ингибитора jak киназы для лечения респираторного заболевания - Google Patents

Соединения ингибитора jak киназы для лечения респираторного заболевания

Info

Publication number
EA201891091A1
EA201891091A1 EA201891091A EA201891091A EA201891091A1 EA 201891091 A1 EA201891091 A1 EA 201891091A1 EA 201891091 A EA201891091 A EA 201891091A EA 201891091 A EA201891091 A EA 201891091A EA 201891091 A1 EA201891091 A1 EA 201891091A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
compounds
kinase inhibitor
respiratory disease
inhibitor compounds
Prior art date
Application number
EA201891091A
Other languages
English (en)
Other versions
EA034914B1 (ru
Inventor
Пол Р. Фазери
Джон Р. Джекобсен
Анн-Мари Босолей
Гари И.л. Брандт
Мелисса Флери
Лань Дзян
Камерон Смит
Стивен Д.Е. Салливан
Лори Джин Ван Орден
Пьер-Жан Кольсон
Джин Тимоти Фэсс
Мирослав Рапта
Ноа Бенджамин
Марта Дэброс
Венкат Р. Таллади
Original Assignee
ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи filed Critical ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи
Publication of EA201891091A1 publication Critical patent/EA201891091A1/ru
Publication of EA034914B1 publication Critical patent/EA034914B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретение относится к соединениям формулы (I),где X представляет собойи переменные имеют значения, как определены в описании, или их фармацевтически приемлемым солям, которые являются полезными в качестве ингибиторов JAK-киназы. Изобретение также относится к фармацевтическим композициям, содержащим такие соединения, к способам использования таких соединений для лечения респираторных заболеваний, а также к способам и промежуточным соединениям, пригодным для получения таких соединений.
EA201891091A 2015-11-03 2016-11-02 Соединения ингибитора jak-киназы для лечения респираторного заболевания EA034914B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250113P 2015-11-03 2015-11-03
PCT/US2016/059999 WO2017079205A1 (en) 2015-11-03 2016-11-02 Jak kinase inhibitor compounds for treatment of respiratory disease

Publications (2)

Publication Number Publication Date
EA201891091A1 true EA201891091A1 (ru) 2018-12-28
EA034914B1 EA034914B1 (ru) 2020-04-06

Family

ID=57442794

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891091A EA034914B1 (ru) 2015-11-03 2016-11-02 Соединения ингибитора jak-киназы для лечения респираторного заболевания

Country Status (21)

Country Link
US (6) US10100049B2 (ru)
EP (1) EP3371186A1 (ru)
JP (1) JP6800969B2 (ru)
KR (1) KR20180073687A (ru)
CN (1) CN108349972B (ru)
AU (1) AU2016350816B2 (ru)
BR (1) BR112018008966B1 (ru)
CA (1) CA3001542C (ru)
CL (1) CL2018001145A1 (ru)
CO (1) CO2018005640A2 (ru)
EA (1) EA034914B1 (ru)
HK (1) HK1252685A1 (ru)
IL (1) IL258772B (ru)
MX (1) MX2018005446A (ru)
MY (1) MY195427A (ru)
NZ (1) NZ741737A (ru)
PH (1) PH12018500828A1 (ru)
SA (1) SA518391470B1 (ru)
TW (1) TWI710560B (ru)
UA (1) UA123633C2 (ru)
WO (1) WO2017079205A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2820445C2 (ru) * 2019-02-25 2024-06-03 Хенан Мединно Фармасьютикал Текнолоджи Ко., Лтд. Соединение-ингибитор jak и его применение

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3001542C (en) 2015-11-03 2021-02-16 Theravance Biopharma R&D Ip, Llc Jak kinase inhibitor compounds for treatment of respiratory disease
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
PT3371185T (pt) 2015-11-03 2020-12-28 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
SG11201907840RA (en) 2017-03-09 2019-09-27 Theravance Biopharma R&D Ip Llc Fused imidazo-piperidine jak inhibitors
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
SG11201909376TA (en) * 2017-05-01 2019-11-28 Theravance Biopharma R&D Ip Llc Crystalline forms of a jak inhibitor compound
AU2018261588A1 (en) * 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
WO2019104225A1 (en) 2017-11-22 2019-05-31 Dauntless 2, Inc. Therapeutic compound formulations
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
CA3108848A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
IL281146B2 (en) 2018-09-04 2023-12-01 Theravance Biopharma R& D Ip Llc Dimethyl amino aztidine amides as JAK inhibitors
AU2019335200A1 (en) 2018-09-04 2021-03-11 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as JAK inhibitors
EP3853229A1 (en) * 2018-10-29 2021-07-28 Theravance Biopharma R&D IP, LLC 2-azabicyclo hexane compound as jak inhibitor
KR20210132666A (ko) * 2019-02-25 2021-11-04 허난 메디노 파마슈티컬 테크놀로지 컴퍼니 리미티드 Jak 억제제 화합물 및 그 사용
CN114007621A (zh) 2019-03-05 2022-02-01 因赛特公司 用于治疗慢性肺同种异体移植物功能障碍的jak1途径抑制剂
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
EP4071145A4 (en) * 2019-12-30 2023-04-19 Liang Lu JAK INHIBITOR COMPOUND AND ITS USE
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2022178215A1 (en) 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
US20220306626A1 (en) * 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound
EP4359402A1 (en) * 2021-06-25 2024-05-01 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors
CN114181055A (zh) * 2021-12-21 2022-03-15 苏州楚凯药业有限公司 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法
WO2023215478A1 (en) 2022-05-05 2023-11-09 Theravance Biopharma R&D Ip, Llc Nezulcitinib for delivery by nebulized oral inhalation

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
JP4836788B2 (ja) 2003-07-23 2011-12-14 エグゼリクシス， インコーポレイテッド 未分化リンパ腫キナーゼ変調因子及びその使用法
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
ATE497496T1 (de) 2006-10-19 2011-02-15 Rigel Pharmaceuticals Inc 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
CA2727036C (en) 2008-06-20 2017-03-21 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
US20110184013A1 (en) 2008-10-01 2011-07-28 Shelley Allen Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
US20110028503A1 (en) 2009-07-28 2011-02-03 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP3305073B1 (en) * 2009-12-21 2019-05-15 Samumed, LLC 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
CN103476770B (zh) 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 阿法替尼盐和多晶型物
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
TW201513861A (zh) * 2013-01-17 2015-04-16 Galapagos Nv 用於治療退化性及發炎疾病之新穎化合物
UA117040C2 (uk) 2013-12-05 2018-06-11 Пфайзер Інк. ПІРОЛО[2,3-d]ПІРИМІДИНІЛ-, ПІРОЛО[2,3-b]ПІРАЗИНІЛ- ТА ПІРОЛО[2,3-d]ПІРИДИНІЛАКРИЛАМІДИ
KR20170002623A (ko) 2014-05-14 2017-01-06 화이자 인코포레이티드 피라졸로피리딘 및 피라졸로피리미딘
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
PT3371185T (pt) 2015-11-03 2020-12-28 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
CA3001542C (en) 2015-11-03 2021-02-16 Theravance Biopharma R&D Ip, Llc Jak kinase inhibitor compounds for treatment of respiratory disease
SG11201907840RA (en) 2017-03-09 2019-09-27 Theravance Biopharma R&D Ip Llc Fused imidazo-piperidine jak inhibitors
SG11201909376TA (en) 2017-05-01 2019-11-28 Theravance Biopharma R&D Ip Llc Crystalline forms of a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
AU2019335200A1 (en) 2018-09-04 2021-03-11 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as JAK inhibitors
CA3108848A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
IL281146B2 (en) 2018-09-04 2023-12-01 Theravance Biopharma R& D Ip Llc Dimethyl amino aztidine amides as JAK inhibitors
EP3853229A1 (en) 2018-10-29 2021-07-28 Theravance Biopharma R&D IP, LLC 2-azabicyclo hexane compound as jak inhibitor
US20220306626A1 (en) 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2820445C2 (ru) * 2019-02-25 2024-06-03 Хенан Мединно Фармасьютикал Текнолоджи Ко., Лтд. Соединение-ингибитор jak и его применение

Also Published As

Publication number Publication date
US11718616B2 (en) 2023-08-08
IL258772A (en) 2018-06-28
US11299492B2 (en) 2022-04-12
CO2018005640A2 (es) 2018-05-31
CL2018001145A1 (es) 2018-07-06
BR112018008966B1 (pt) 2023-05-02
US20170121327A1 (en) 2017-05-04
CA3001542C (en) 2021-02-16
US20210130351A1 (en) 2021-05-06
IL258772B (en) 2021-01-31
EA034914B1 (ru) 2020-04-06
MX2018005446A (es) 2018-08-01
AU2016350816A1 (en) 2018-05-17
US10913740B2 (en) 2021-02-09
PH12018500828A1 (en) 2018-10-29
US10100049B2 (en) 2018-10-16
NZ741737A (en) 2023-11-24
TW201726673A (zh) 2017-08-01
US20200087303A1 (en) 2020-03-19
CN108349972A (zh) 2018-07-31
US10526330B2 (en) 2020-01-07
JP6800969B2 (ja) 2020-12-16
EP3371186A1 (en) 2018-09-12
KR20180073687A (ko) 2018-07-02
BR112018008966A2 (pt) 2018-11-27
UA123633C2 (uk) 2021-05-05
AU2016350816B2 (en) 2020-06-25
HK1252685A1 (zh) 2019-05-31
CN108349972B (zh) 2021-06-08
US20180319796A1 (en) 2018-11-08
US10183942B2 (en) 2019-01-22
CA3001542A1 (en) 2017-05-11
US20220306624A1 (en) 2022-09-29
JP2018531982A (ja) 2018-11-01
WO2017079205A1 (en) 2017-05-11
US20190106420A1 (en) 2019-04-11
TWI710560B (zh) 2020-11-21
MY195427A (en) 2023-01-20
SA518391470B1 (ar) 2021-03-31

Similar Documents

Publication Publication Date Title
EA201891091A1 (ru) Соединения ингибитора jak киназы для лечения респираторного заболевания
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA201892207A1 (ru) Индолкарбоксамидные соединения
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
EA201792619A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201792116A1 (ru) Ингибитор янус-киназы
EA201690752A1 (ru) Ингибиторы g12c kras
EA201791576A1 (ru) Ингибитор jak
EA201892436A1 (ru) Пиримидиновые соединения в качестве ингибиторов jak киназы
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
EA201590358A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201600636A1 (ru) 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака